Wednesday, April 22

Browsing: pemigatinib

Research

N6-methyladenosine–mediated up-regulation of ARRB2 regulates intrahepatic cholangiocarcinoma malignant progression and pemigatinib resistance through MAPK and Hippo signaling pathways

By NewsCancerApril 15, 20260

Brindley PJ, Bachini M, Ilyas SI, Khan SA, Loukas A, Sirica AE, et al. Cholangiocarcinoma. Nat Rev Dis Primers. 2021;7:65.…

Research

The FGFR1 N546K mutation confers resistance to pemigatinib in MLN-ZMYM2::FGFR1

By NewsCancerFebruary 21, 20260

Myeloid/lymphoid neoplasms with fibroblast growth factor receptor 1 (FGFR1) gene fusions (MLN-FGFR1) are rare haematological neoplasms characterized by an aggressive…

► Necessary Cookies Always Active

Necessary cookies enable essential site features like secure log-ins and consent preference adjustments. They do not store personal data.

► Functional Cookies Remark

Functional cookies support features like content sharing on social media, collecting feedback, and enabling third-party tools.

► Analytical Cookies Remark

Analytical cookies track visitor interactions, providing insights on metrics like visitor count, bounce rate, and traffic sources.

► Advertisement Cookies Remark

Advertisement cookies deliver personalized ads based on your previous visits and analyze the effectiveness of ad campaigns.

What's Hot

AACR in 30 Seconds: Revolution Medicines data, NCI director, wildfires

HDAC8 inhibition targets STAT3–MYC axis and synergizes with Venetoclax in KMT2A-rearranged acute myeloid leukemia

Mastectomy, ET Linked to Lower LRR in Young Populations With Breast Cancer

Browsing: pemigatinib

N6-methyladenosine–mediated up-regulation of ARRB2 regulates intrahepatic cholangiocarcinoma malignant progression and pemigatinib resistance through MAPK and Hippo signaling pathways

The FGFR1 N546K mutation confers resistance to pemigatinib in MLN-ZMYM2::FGFR1

AACR in 30 Seconds: Revolution Medicines data, NCI director, wildfires

HDAC8 inhibition targets STAT3–MYC axis and synergizes with Venetoclax in KMT2A-rearranged acute myeloid leukemia

Mastectomy, ET Linked to Lower LRR in Young Populations With Breast Cancer

Revolution Medicines previews ‘novel class’ of cancer treatments

AACR in 30 Seconds: Revolution Medicines data, NCI director, wildfires

HDAC8 inhibition targets STAT3–MYC axis and synergizes with Venetoclax in KMT2A-rearranged acute myeloid leukemia

Mastectomy, ET Linked to Lower LRR in Young Populations With Breast Cancer

Revolution Medicines previews ‘novel class’ of cancer treatments

Latest Post

AACR in 30 Seconds: Revolution Medicines data, NCI director, wildfires

HDAC8 inhibition targets STAT3–MYC axis and synergizes with Venetoclax in KMT2A-rearranged acute myeloid leukemia

Mastectomy, ET Linked to Lower LRR in Young Populations With Breast Cancer

Subscribe to Updates

What's Hot

Browsing: pemigatinib